Technology | 2019.09.24
Catalent and Minerva Neurosciences Enter Commercial Supply Agreement for Schizophrenia Drug Roluperidone
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, and Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that they have entered into a long-term commercial supply agreement for roluperidone (MIN-101), an investigational compound under development by Minerva Neurosciences, Inc., for the treatment of negative symptoms of schizophrenia. Under the terms of the agreement, Catalent will manufacture and package the finished dose form of the drug at its facility in Schorndorf, Germany.
(PRWeb September 24, 2019)
Read the full story at https://www.prweb.com/releases/catalent_and_minerva_neurosciences_enter_commercial_supply_agreement_for_schizophrenia_drug_roluperidone/prweb16594889.htm
For more information, please visit
https://www.prweb.com/releases/catalent_[...]roluperidone/prweb16594889.htm
